Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Premature (Early) Ejaculation
In brief
The goal of this clinical trial is to learn if drug BP1.4979 works to treat primary premature ejaculation in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are: * Does drug BP1.4979 increase the time to ejaculation during sexual intercourse? * Do participants have a good safety and tolerability of drug BP1.4979? Researchers will compare drug BP1.4979 to a placebo (a look-alike substance that contains no drug) to see if drug BP1.4979 works to treat primary premature ejaculation. Participants will: * Take drug primary premature ejaculation or a placebo per requested need prior to sexual intercourses for 12 weeks * Visit the clinic 4 times for checkups and questionnaires completion and have 2 phone calls with the study team over a period of about 17 weeks * Keep a diary of the intakes of the experimental drug, ejaculation time, ejaculation control, any unusual events concerning their health and any other medication taken
Key facts
- Study ID
- NCT07047404
- Run by
- Bioprojet
- People needed
- 60
- Starts
- 2025-09-15
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2025-10-06
Who can join
Age: 18 and older, up to 50. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Males aged 18 to 50 years old (both inclusive)
- Diagnosis of primary (lifelong) PE according to the investigator
- Intravaginal Ejaculatory Latency Time (IELT) estimated by the patient around one (1) minute at screening
- Confirmation at randomization visit that at least 3 timed sexual intercourses with each IELT below 90 seconds occurred during the baseline period
- Patient must be able to provide an informed consent and voluntarily express a willingness to participate in this study, and must sign and date an informed consent prior to any study specific procedure
- Capability to participate in all study tests according to the investigator
You may not qualify if…
- Diagnosis of acquired PE, pseudo-PE or natural variable PE
- History of clinically significant abnormalities comprising cardiovascular (including especially prolonged QTc (>450 ms) and high degree (second and third) atrio-ventricular blocks)), hematological, neurological, and endocrine diseases
- Current therapy with any treatment which may impact PE from 4 weeks prior to the screening visit
- Current therapy with any treatment displaying dopamine D3 receptor agonist properties from 4 weeks prior to the screening visit
- Concomitant intake of psychoactive / chem-sex substances
Where it is running
- University Hospital of Nîmes — Nîmes, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.